1.
Lebwohl MG, Mehta NN, Gottlieb AB, Mendelsohn AM. Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies. J of Skin [Internet]. 2020Sep.2 [cited 2022Jul.5];4(5):s42. Available from: https://www.jofskin.org/index.php/skin/article/view/991